Elsamani I. Abdelfadiel

Elsamani I. Abdelfadiel

Auto-generated profile, based on publicly available information

Elsamani I. Abdelfadiel

Department of Medicinal Chemistry, School of Pharmacy, Virginia Commonwealth University, Richmond, VA

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 November 2026 in Blood Advances
Verified
Journal Article
Closed access
CSChiranjeev Sharma
Chiranjeev Sharma
RGRama Gunta
Rama Gunta
SISridhar R. Iyer
Sridhar R. Iyer
RFRawan M. Fayyad
Rawan M. Fayyad
EAElsamani I. Abdelfadiel
Elsamani I. Abdelfadiel
Umesh DesaiUmesh Desai
Umesh Desai
Only a handful of anticoagulants have reached the clinic to treat and prevent thrombotic episodes in the millions of patients with cardiovascular, cancer, viral (COVID-19), and metabolic diseases. In this study, we report the discovery, chemical synthesis, mechanistic biochemistry, pharmacology, and toxicology of SB-01, a novel, allosteric, activated human factor XIa (hFXIa) inhibitor that displays potent antithrombotic activity in preclinical models. SB-01 is a synthetic, highly sulfated, aromatic agent that binds in both anion-binding exosites of hFXIa to induce inhibition of FIX activation. SB-01 inhibited rodent arterial and venous thrombosis at doses of 6 and 3 mg/kg, respectively. In addition, a twice-a-day regimen of 6 mg/kg SB-01 was significantly more effective (P< .001) in preventing deep vein thrombosis in animals with lung cancer. Michaelis-Menten kinetics and competition with unfractionated heparin and polyphosphate revealed SB-01 to be an allosteric inhibitor. Critically, at the effective dose of 6 mg/kg, SB-01 did not significantly increase mouse tail bleeding time or blood loss. Furthermore, SB-01’s anticoagulation could be readily reversed with protamine sulfate, the US Food and Drug Administration–approved antidote for heparin. Finally, SB-01 showed no major adverse effects across multiple toxicological assays including gross, cardiac, metabolic, hematological, and clinical chemistry. Overall, this study presents a structurally and functionally unique, allosteric small molecule as a highly promising candidate for safer anticoagulation.